Key Findings
The Asia-Pacific cannabis testing market is anticipated to rise at a CAGR of 15.37% over the forecast period of 2018 to 2026. Cannabis is widely used for pain management and is often used in the medical industry to cure and treat certain disorders such as epilepsy, brain tumors etc.; which increases the demand for cannabis testing in the Asia Pacific market.

Market Insights
The recent legalization of cannabis for medical and therapeutic use in many Asian countries combined with the high venture funding for cannabis testing is mainly responsible for driving the Asia-Pacific cannabis testing market. The market is segmented according to the testing methods, end-users, product and software, and the cannabis type. However, there is a possibility of the market facing some restraints on account of the low availability of technicians and scientist in the field and the high capital required for initial setup of the testing facility.

Competitive Insights
Accelerated Technology Laboratories Inc, Genentech Scientific, Thermo Fisher Scientific Inc, Cannasafe Analytics, Agilent Technologies Inc, Perkinelmer Inc, Pharmlabs LLC, etc. are few of the leading companies in this market.